Arteaus Therapeutics, LLC
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arteaus Therapeutics, LLC
Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.
Deborah Dunsire’s appointment to lead Lundbeck tops this week’s list of new hires; Astellas, Orchard Therapeutics, Voyager Therapeutics, iTeos Therapeutics, Cevec Pharmaceuticals, Sangamo Therapeutics, Cedilla Therapeutics, Tilos Therepautics and Neos Therapeutics have also appointed new executives and directors.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Amgen will be the first biopharma company to seek approval for a CGRP inhibitor when it submits a BLA for FDA approval later in the second quarter, but Alder, Lilly, Teva and Allergan are in the running for best-in-class status to treat unmet needs in migraine and other headache markets.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.